2021
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.Peer-Reviewed Original ResearchConceptsPrior endocrine therapyEndocrine therapyMetastatic breast cancerEffective treatment optionTreatment optionsBreast cancerMedian treatmentMedian OSEE therapyHormone receptor-positive HER2-negative metastatic breast cancerMultivariable Cox proportional hazards regression analysisHER2-negative metastatic breast cancerPrior treatmentCox proportional hazards regression analysisFirst-line therapy initiationProportional hazards regression analysisPrior treatment optionsLines of therapyProportion of patientsKaplan-Meier methodHazards regression analysisPatterns of treatmentElectronic health record-derived dataClinical trial dataOS benefit
2019
Treatment-Related Complications of Systemic Therapy and Radiotherapy
Jairam V, Lee V, Park HS, Thomas CR, Melnick ER, Gross CP, Presley CJ, Adelson KB, Yu JB. Treatment-Related Complications of Systemic Therapy and Radiotherapy. JAMA Oncology 2019, 5: 1028-1035. PMID: 30946433, PMCID: PMC6583836, DOI: 10.1001/jamaoncol.2019.0086.Peer-Reviewed Original ResearchConceptsTreatment-related complicationsOverall ED visitsAcute kidney injuryED visitsSystemic therapyInpatient admissionsEmergency departmentKidney injuryCommon complicationMAIN OUTCOMEUtilization Project Nationwide Emergency Department SampleFinancial burdenNationwide Emergency Department SampleHospital-related factorsClinical Modification codesEmergency Department SampleClinical Classification SoftwareTotal financial burdenInternational Statistical ClassificationOverall financial burdenHigh rateRelated Health ProblemsAcute complicationsStudy cohortNinth RevisionImplementing an Electronic End-of-Life Chemotherapy Utilization Measure
Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, Meropol NJ. Implementing an Electronic End-of-Life Chemotherapy Utilization Measure. JCO Oncology Practice 2019, 15: jop.18.00408. PMID: 30883256, DOI: 10.1200/jop.18.00408.Peer-Reviewed Original Research
2018
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting
Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting. JAMA 2018, 320: 469-477. PMID: 30088010, PMCID: PMC6142984, DOI: 10.1001/jama.2018.9824.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDNA, NeoplasmFemaleGenes, erbB-1GenomicsGenotypeHumansImmunotherapyLung NeoplasmsMaleMiddle AgedMutationNeoplasm StagingReceptor Protein-Tyrosine KinasesRetrospective StudiesSequence Analysis, DNASurvival AnalysisConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCommunity oncology settingCell lung cancerLung cancerOncology settingRoutine testingNonsquamous non-small cell lung cancerTargeted treatmentPropensity score-matched survival analysisStage IIIB/IVFlatiron Health databaseIIIB/IVRetrospective cohort studyThird-line treatmentFirst-line treatmentMinority of patientsUnadjusted mortality ratesEGFR/ALKCohort studyOverall survivalSecondary outcomesUnmatched cohortPrimary outcomeAntineoplastic treatment
2015
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncology 2015, 1: 778-784. PMID: 26203912, PMCID: PMC4828728, DOI: 10.1001/jamaoncol.2015.2378.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChi-Square DistributionFemaleHealth StatusHealth Status IndicatorsHumansLogistic ModelsLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisNeoplasm MetastasisNeoplasm StagingNeoplasmsOdds RatioPalliative CarePatient SelectionProportional Hazards ModelsProspective StudiesQuality of LifeRisk AssessmentRisk FactorsStress, PsychologicalSurveys and QuestionnairesTerminal CareTime FactorsTreatment OutcomeUnited StatesConceptsEnd-stage cancerGood performance statusBaseline performance statusQuality of lifeChemotherapy usePatient performance statusPerformance statusPalliative chemotherapyEastern Cooperative Oncology Group performance statusGood baseline performance statusPoor baseline performance statusProgressive metastatic cancerProgressive metastatic diseasePoor performance statusSolid tumor patientsClinical Oncology guidelinesLongitudinal cohort studyOutpatient oncology clinicsChemotherapy regimenEnd of lifeCohort studyMetastatic diseaseOncology clinicPatient survivalOncology guidelines
2013
Implementation of Electronic Chemotherapy Ordering: An Opportunity to Improve Evidence-Based Oncology Care
Adelson KB, Qiu YC, Evangelista M, Spencer-Cisek P, Whipple C, Holcombe RF. Implementation of Electronic Chemotherapy Ordering: An Opportunity to Improve Evidence-Based Oncology Care. JCO Oncology Practice 2013, 10: e113-e119. PMID: 24371301, DOI: 10.1200/jop.2013.001184.Peer-Reviewed Original ResearchConceptsElectronic health recordsEvidence-based practiceEvidence-based adherenceEvidence-based treatmentsAntiemetic useChemotherapy prescribingSupportive careChemotherapy protocolsInfusion scheduleSociety guidelinesOncology careDisease groupOncology practiceChemotherapy orderingProvider satisfactionPrespecified goalsPatient carePatient safetyExtensive involvementHealth recordsCareChemotherapyWait timeAdherenceClinical operations